Fact CheckerSign in

NCT07701525CompletedPhase 4

Myo-Inositol and D-Chiro-Inositol for Menstrual Irregularities and Hormone Changes in Women With Polycystic Ovarian Syndrome

Effect of Myo-Inositol and D-Chiro-Inositol Combination Therapy on Improvement in Menstrual Irregularities and Biochemical Characteristics in Patients With Polycystic Ovarian Syndrome

Source: ClinicalTrials.gov · Last updated 14 Jul 2026

Brief summary (registry, in English)

The goal of this clinical trial is to determine whether a combination of myo-inositol (MI) and D-chiro-inositol (DCI) with folic acid is more effective than placebo (Folic acid alone) in improving menstrual irregularities and hormone levels in women with polycystic ovarian syndrome (PCOS). The main questions this study aims to answer are: 1. Does treatment with myo-inositol and D-chiro-inositol improve menstrual regularity in women with PCOS compared with placebo? 2. Does the treatment improve biochemical characteristics, including luteinizing hormone (LH), follicle-stimulating hormone (FSH), and testosterone levels, compared with placebo? Researchers will compare a combination of myo-inositol and D-chiro-inositol with a placebo (folic acid alone) to determine whether the combination therapy is more effective in treating PCOS-related menstrual and hormonal abnormalities. Participants will: * Be randomly assigned to receive either a myo-inositol and D-chiro-inositol combination tablet (40:1 ratio) or placebo twice daily for 3 months. * Have blood samples collected before starting treatment and after 3 months to measure LH, FSH, and testosterone levels. * Attend monthly follow-up visits during the 3-month treatment period to assess changes in menstrual regularity and monitor their progress. The study will enroll 60 women aged 18-45 years with PCOS at the Department of Obstetrics and Gynecology, Nishtar Hospital Multan. The results may help determine whether myo-inositol and D-chiro-inositol combination therapy is an effective treatment for improving menstrual function and hormonal abnormalities in women with PCOS.

Status (registry)
Completed
Phase (registry)
Phase 4
Study type
Interventional
Enrollment
60 (actual)
First submitted
8 Jul 2026
Start date
1 Jun 2025
Primary completion date
30 Nov 2025
Lead sponsor
Nishtar Medical University
NCT number
NCT07701525

What you commit to

  • Study type: Interventional · Phase 4
  • Participants enrolled: 60
  • From 1 Jun 2025 to the primary completion date, 30 Nov 2025
  • 1 site in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Other illness

  • Hyperprolactinemia, hypothyroidism, adrenal hyperplasia or Cushing's syndrome (on history \& medical record review)

Who the study is looking for

  • diagnosed case of PCOS, ≥ 6-months

Age in the registry: 18 years to 45 years · Sex: Female · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (1)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
Nishtar Medical University and Hospital Multan
Coordinator of this site? Confirm its status
MultanPakistanUnknown status

This page is information, not medical advice. Discuss any trial with your doctor.